APG777 for Moderate to Severe Atopic Dermatitis Study in NYC
ENROLLING — This two-part study will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD).
APG777 for Moderate to Severe Atopic Dermatitis Study in Kentucky
ENROLLING — This two-part study will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD).
Rinvoq vs. Dupixent for Children Atopic Dermatitis Study in Kentucky
ENROLLING — Join our Phase 3 study in Kentucky comparing Upadacitinib and Dupilumab for children 6 to under 12 with moderate to severe atopic dermatitis.
Rinvoq vs. Dupixent for Atopic Dermatitis Study in NYC
ENROLLING — Be part of our SWITCH-UP Atopic Dermatitis trial in NYC to explore Rinvoq as an alternative for those unresponsive to Dupixent.
Amlitelimab in Moderate-to-Severe Atopic Dermatitis Trial in Kentucky
Explore Amlitelimab, an innovative treatment for Atopic Dermatitis, in our COAST 2 clinical trial located in Kentucky.
Clinical Trial Study for Atopic Dermatitis
ENROLLING — Learn more about our Amlitelimab trial targeting moderate-to-severe Atopic Dermatitis in NYC.